StockNow
Log in
Global Markets

GSK's (GSK LN) nucala (mepolizumab) receives positive reimbursement recommendation from cda-amc for adults with chronic obstructive pulmonary disease

StockNow breaking-news AI analysis

Nucala received a positive Canadian reimbursement recommendation for COPD, leveraging strong Phase III data and previous EU/US approvals to drive GSK's respiratory franchise growth amid competitive market risks.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Politics

US President Trump posts "There are no talks or conversations going on, or scheduled, with the Islamic Republic of Iran. The Naval Blockade remains in full force and effect. The Hormuz Strait is open and operating"

U.S. Economy

Atlanta Fed GDP Now (Q3 2026): 4.0% (prev. 4.3%)

Geopolitics

"Warning sirens heard in Dubai", Tasnim reports; detected a missile threat targeting the country